---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-233038"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2024-10-04T23:59:59+00:00"
generated_at: "2026-05-30T20:21:44.028855+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IDEAYA to present Phase 1 expansion data for IDE397 in MTAP-deletion NSCLC/urothelial at EORTC-NCI-AACR

## Summary
- Phase 1 expansion results for IDE397 (MAT2A inhibitor) in MTAP-deletion NSCLC and urothelial cancer to be presented as late-breaker oral on Oct 25.
- Presenter is Dr. Benjamin Herzberg, Columbia University; abstract #501 LBA.
- Additional poster: preclinical data for MAT2A + PRMT5 combination in MTAP-deleted tumors (poster PB204).
- Additional poster: preclinical data for IDE161, a PARG inhibitor targeting solid tumors (poster PB337).
- EORTC-NCI-AACR Symposium in Barcelona, Oct 23-25, 2024.

## SEC filing metadata
- accession: 0001193125-24-233038
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2024-10-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000119312524233038/0001193125-24-233038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000119312524233038/d828798d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-233038
- JSON: https://secwatch.observer/filing/0001193125-24-233038.json
- Plain text: https://secwatch.observer/filing/0001193125-24-233038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.